'''Filaminast''' (code name '''WAY-PDA 641''')<ref>[https://pubchem.ncbi.nlm.nih.gov/compound/9578243?from=summary#section=Top Filaminist entry at Pubchem]</ref> was a drug candidate developed by Wyeth-Ayerst.<ref>Halpin DM. ABCD of the phosphodiesterase family: interaction and differential activity in COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(4):543-61. {{PMID|19281073}} {{PMC|2650605}}</ref>{{rp|Table 2}} It is a phosphodiesterase 4 inhibitor ([[PDE4 inhibitor]]) and an analog of [[rolipram]], which served as a prototype molecule for several development efforts.<ref>{{Cite journal|doi=10.1038/bjp.2008.297|pmc=2567889|pmid=18660832|title=Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?|year=2008|last1=Giembycz|first1=M A|journal=British Journal of Pharmacology|volume=155|issue=3|pages=288â€“90}}</ref><ref name=McKenna>McKenna, JM and Muller, GW.  Medicinal Chemistry of PDE4 Inhibitors. Chapter 33 in Cyclic Nucleotide Phosphodiesterases in Health and Disease, Eds Joseph A. Beavo et al. CRC Press, Dec 5, 2006 {{ISBN|9781420020847}}</ref>{{rp|668, 678}} It was discontinued after a Phase II trial showed that its [[therapeutic window]] was too narrow; it could not be dosed high enough without causing significant side effects (nausea and vomiting), which was a problem with the rolipram class of molecules.<ref name=McKenna/>{{rp|678}}
